Evofem Biosciences Reports Material Agreement
Ticker: EVFM · Form: 8-K · Filed: Apr 14, 2025 · CIK: 1618835
Sentiment: neutral
Topics: material-agreement, filing, financials
Related Tickers: EVFM
TL;DR
EVFM signs new material agreement, filing includes financials.
AI Summary
Evofem Biosciences, Inc. filed an 8-K on April 14, 2025, reporting a material definitive agreement entered into on April 8, 2025. The filing also includes financial statements and exhibits. The company, formerly known as Neothetics, Inc., is based in San Diego, California.
Why It Matters
This filing indicates a significant new agreement for Evofem Biosciences, which could impact its financial standing and future operations. Investors should monitor the details of this agreement.
Risk Assessment
Risk Level: medium — The filing reports a material definitive agreement, which could carry significant implications for the company's future, but the specific details and impact are not yet fully disclosed in this initial report.
Key Players & Entities
- Evofem Biosciences, Inc. (company) — Registrant
- Neothetics, Inc. (company) — Former company name
- April 8, 2025 (date) — Date of earliest event reported
- April 14, 2025 (date) — Date of report
- San Diego, California (location) — Company address
FAQ
What is the nature of the material definitive agreement entered into by Evofem Biosciences?
The filing does not specify the details of the material definitive agreement, only that one was entered into on April 8, 2025.
When was this 8-K filing submitted to the SEC?
This 8-K filing was submitted on April 14, 2025.
What was Evofem Biosciences' former company name?
Evofem Biosciences, Inc. was formerly known as Neothetics, Inc.
Where is Evofem Biosciences headquartered?
Evofem Biosciences, Inc. is headquartered at 7770 Regents Road, Suite 113-618, San Diego, California 92122.
What is the SIC code for Evofem Biosciences?
The Standard Industrial Classification (SIC) code for Evofem Biosciences is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on April 14, 2025 regarding Evofem Biosciences, Inc. (EVFM).